Article
A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
8 Aug 2012
Abstract excerpt
INTRODUCTION: Recent studies reported that human IgG antibodies are susceptible to specific proteolytic cleavage in their lower hinge region, and the hinge cleavage results in a loss of Fc-mediated effector functions. Trastuzumab is a humanized IgG1 therapeutic monoclonal antibody for the treatment of HER2-overexpressing breast cancers, and its mechanisms of action consist of inhibition of HER2 signaling and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
